IBKS No2 SPAC (204840) - Total Liabilities

Latest as of June 2026: ₩29.11 Billion KRW ≈ $19.73 Million USD

Based on the latest financial reports, IBKS No2 SPAC (204840) has total liabilities worth ₩29.11 Billion KRW (≈ $19.73 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of IBKS No2 SPAC to measure how many days the company can operate on defensive assets alone.

IBKS No2 SPAC - Total Liabilities Trend (2015–2025)

This chart illustrates how IBKS No2 SPAC's total liabilities have evolved over time, based on quarterly financial data. Check 204840 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

IBKS No2 SPAC Competitors by Total Liabilities

The table below lists competitors of IBKS No2 SPAC ranked by their total liabilities.

Company	Country	Total Liabilities
Krynica Vitamin SA WAR:KVT	Poland	zł104.22 Million
Fernheizwerk Neukölln Aktiengesellschaft F:FHW	Germany	€46.74 Million
Sunzen Biotech Bhd KLSE:0148	Malaysia	RM18.73 Million
Tevogen Bio Holdings Inc. NASDAQ:TVGN	USA	$13.62 Million
Global Knafaim Leasing Ltd TA:GKL	Israel	ILA49.12 Million
I-Hwa Industrial Co Ltd TW:1456	Taiwan	NT$11.68 Billion
BII Railway Transportation Technology Holdings Company Limited F:CN6	Germany	€1.97 Billion
Medicamen Biotech Limited NSE:MEDICAMEQ	India	Rs-2.76 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down IBKS No2 SPAC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IBKS No2 SPAC total assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.59	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how IBKS No2 SPAC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for IBKS No2 SPAC (2015–2025)

The table below shows the annual total liabilities of IBKS No2 SPAC from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩28.90 Billion ≈ $19.58 Million	+26.89%
2024-12-31	₩22.77 Billion ≈ $15.43 Million	-17.45%
2023-12-31	₩27.59 Billion ≈ $18.69 Million	+11.40%
2022-12-31	₩24.76 Billion ≈ $16.78 Million	+64.59%
2021-12-31	₩15.05 Billion ≈ $10.20 Million	-27.07%
2020-12-31	₩20.63 Billion ≈ $13.98 Million	-14.70%
2019-12-31	₩24.19 Billion ≈ $16.39 Million	+1.86%
2018-12-31	₩23.74 Billion ≈ $16.09 Million	+161.34%
2017-12-31	₩9.09 Billion ≈ $6.16 Million	+140.17%
2016-12-31	₩3.78 Billion ≈ $2.56 Million	-33.42%
2015-12-31	₩5.68 Billion ≈ $3.85 Million	--

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$44.15 Million

₩65.14 Billion KRW

Market Cap Rank

#22425 Global

#1456 in Korea

Share Price

₩4200.00

Change (1 day)

+1.45%

52-Week Range

₩780.00 - ₩5780.00

All Time High

₩8655.23